Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Monday, October 5, 2026

Back to today

From X

@ActAccordingly

PAA Research on X

I still own $AIRS and think it will work. The company is in a much better financial and operational position than it was a year ago. Heading into the quarter, I thought they would post 3-5% same center comps, instead we got a 1% and they stated June/July was "soft". Guidance came down $1.0-$1.5MM for EBITDA, probably not the stuff (-40%+) declines are made of, but you have a ton of fast money and retail here. Brutal. However, the company spent a fair amount on top of the funnel brand marketing the past 3-6 months, the returns on that spend are longer tail in nature. Leverage is <2.0x now. They keep adding to the "menu" for procedures, which should drive significant improvements in site utilization and incremental margins that could approach 40-50%. This business has the potential to reach 150-200 units at 20-25% EBITDA margins. That would represent $1.0B in topline and $200MM+ of EBITDA. Obviously that doesn't happen anytime soon, but they can get back to de novo site expansion of 2-4 units a year starting in 2027 to get the growth flywheel going. The industry remains incredibly fragmented and the GLP-1 tailwinds for aesthetics are quite real. It's kind of remarkable the stock trades like this given the size of the float, which is probably only 12-13MM shares. Hopefully we'll see some insider buying in the coming days. At these levels, this would be an attractive asset for quite a few potential buyers IMO.
@majgeoinvesting

Maj Soueidan on X

Linda actually just bought a little not too long ago. So, not sure she’s a seller anytime soon. But, I need to be honest. I really liked Linda. I viewed her as one of those high quality CEOs you rarely see at the microcap level. I’m surprised/saddened she’s moved on from $KRMD, although she’s exiting at the top of some of her accomplishments at the company. •Pharma partner platform •Product innovation (high volume infusion, pre-filled syringes) •Reaching profitability, although minor. This is where I was hoping to see better traction (been a while since i looked, but not sure if they hit original timeline on gross margin target). All and all, KRMD is a recurring revenue machine. I’m surprised no one has bought them yet. The new CEO looks legit, but I would have loved to have seen Thomas Patton involved in the company, at least at the Board level. He never seemed interested whenever I brought it up - when the founder and Board were battling. So much of what he has touched has turned into home runs and in exits… Although $ECOR didn’t quite workout, but to be fair, he was only on the Board. His CEO record is impeccable. @ipo_candy @MoneyMarkStocks @neilcataldi - Tom should be your next call.

Investor Letters

All letters

Not So Fast

Entravision, the portfolio’s largest position, fell more than 40% from its highs as Q3 returns dropped to 37.8% YTD.

EVC $598M
The Mikro Kap 1 click

Zentek Research Note

Zentek shipped its first ZenGUARD air-filter order to a Canadian federal facility as its Albany graphite PEA confirmed a US$3.85 billion…

ZTEKF $58M
Atrium Research - Equity Research 1 click

💥Yield!💥

Beyond Meat’s Q2 2026 revenue fell 8.2% as U.S. retail and foodservice volumes declined, while a flatter, not inverted, Treasury curve…

BYND $132M
PETITION

Updates

FGPR remains on track, PRTH's management buyout is set at $8.05, and microcap RAVE is described as cheap.

FGPR $248MPRTH $644M
Nat Stewart - Stock Picking Newsletter 9 clicks

Is The Bond Market Running On Empty?

U.S. Treasury yields are testing credit and equity markets, while the discussion also targets recent changes at Glass House (GLAS).

GLAS $401M
WHAT ARE WE DOING? “Contrarians At The Gate” 1 click

IEH Corporation: Research Note

IEH booked $3.6 million in mobile-defibrillator connector orders, lifting its medical revenue outlook and diversifying beyond aerospace and…

IEHC $74M
Atrium Research - Equity Research 7 clicks

Publications we follow

Every publication on this site, hand-picked.

128 publications

Newsletters 106

YouTube 4

Blogs 17

Seeking Alpha 47 of 224

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

84 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.